How to Help Your Patients Save Money on COVID-19 Antiviral Treatment: A Provider's Guide to Savings Programs

Paxlovid's retail price — $1,390 to $1,820 per five-day course — is one of the primary barriers to COVID-19 treatment in 2026. But for most of your patients, the actual out-of-pocket cost should be significantly lower, and for many it can be zero. The key is knowing which programs are available, who qualifies, and how to streamline enrollment at the point of prescribing.

This guide gives you the complete picture of COVID-19 antiviral savings programs in 2026, with practical tools for incorporating cost support into your prescribing workflow.

Program 1: Pfizer PAXCESS — The Most Important Savings Resource

Pfizer's PAXCESS Patient Support Program has two distinct components that cover the majority of your patient population:

PAXCESS Co-Pay Savings Card (Commercially Insured Patients)

• Eligible patients: Patients with commercial or private insurance (not Medicare, Medicaid, or government-funded insurance)
• Benefit: As little as $0 per prescription; maximum annual savings of $1,500
• How to enroll: Patient or provider registers at paxlovid.com and downloads/presents the co-pay card at pharmacy
• Provider role: Your staff can assist enrollment during the visit or provide the patient with the paxlovid.com URL before they leave

PAXCESS U.S. Government Patient Assistance Program (Uninsured / Medicare / Medicaid)

• Eligible patients: Uninsured patients meeting income eligibility; underinsured Medicare/Medicaid patients facing high cost-sharing (income criteria apply)
• Benefit: Paxlovid at no cost while government supply lasts and program is in effect (through December 31, 2026)
• How to enroll: paxlovid.iassist.com or call 1-877-219-7225. Enrollment takes approximately 5 minutes and can be completed by the patient, a caregiver, your staff, or the pharmacist.
• Provider role: Proactive enrollment at the point of prescribing dramatically improves completion rates. Consider adding PAXCESS enrollment to your COVID-positive patient discharge checklist.

Program 2: Insurance Coverage Optimization

Understanding insurance dynamics helps you anticipate and reduce cost barriers for your patients:

• Commercial insurance: Covered by most plans. Copay $0–$75 depending on tier. Pairing with PAXCESS co-pay card often results in $0 patient cost. ACA marketplace plans most likely to require PA.
• Medicare Part D: Required to cover oral COVID-19 antivirals. Variable cost-sharing by plan. The 2026 annual out-of-pocket cap of $2,100 limits maximum patient exposure. Consider the PAXCESS USG PAP for qualifying patients with high copays.
• Prior authorization: Increasingly required. Build a streamlined PA workflow: file PA simultaneously with prescribing; know which local insurers have expedited PA processes for COVID-19 antivirals; maintain a PA denial appeal template for your most common insurers.

38,004+ patients found their medications in stock

38K+

Find Ovide In Stock Today →

Program 3: Gilead Advancing Access for Remdesivir (Veklury)

For patients receiving Remdesivir (Veklury) — either as first-line treatment or because Paxlovid is contraindicated — Gilead Sciences offers financial assistance through the Advancing Access program:

• Program: Gilead's Advancing Access program provides financial support for eligible patients
• Contact: 1-800-226-2056 or veklury.com/patient-support
• Insurance note: Since Remdesivir is IV-administered at a medical facility, Medicare Part B (not Part D) covers it, which can result in lower out-of-pocket costs than expected.

Program 4: MerckHelps for Molnupiravir (Lagevrio)

For patients receiving molnupiravir (Lagevrio) where commercially available, Merck's patient assistance program provides medication at no cost to eligible uninsured patients:

• Contact: merckhelps.com or 1-800-727-5400. Enrollment takes 10–20 minutes.

Skip the calls, skip the stress.

Find Ovide In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Practical Workflow: Incorporating Cost Support Into Your COVID-19 Prescribing Process

Recommended workflow for COVID-positive patients eligible for antiviral treatment:

1. Assess eligibility for antiviral treatment (risk factors, symptom onset timing)
2. Perform drug interaction and renal function screen for Paxlovid
3. Identify patient insurance status (commercial, Medicare, Medicaid, uninsured)
4. Match to appropriate savings program (PAXCESS co-pay card for commercial; USG PAP for uninsured/Medicare/Medicaid)
5. Begin PA process simultaneously with writing the prescription if required by insurer
6. Route prescription to a pharmacy with confirmed stock — use medfinder or hospital outpatient pharmacy
7. Provide patient with assistance program contact info in discharge paperwork

Special Considerations: Patients Who Need Extra Help

• Elderly patients: Medicare beneficiaries are most likely to qualify for USG PAP. The 2026 Medicare Part D cap of $2,100 limits exposure, but many patients may still benefit from PAXCESS enrollment.
• Uninsured patients: PAXCESS USG PAP is the primary resource. Enrollment at point of care is critical — patients told to call later often don't follow through. Take 5 minutes to start enrollment during the visit.
• Patients with prior authorization delays: If PA will take more than 24 hours, PAXCESS assistance may allow the patient to get Paxlovid at the pharmacy while PA is pending. Explore this option before telling a patient to wait for PA.

The Provider's Bottom Line: Cost Support Drives Treatment Completion

COVID-19 antiviral treatment is highly effective, and the financial tools to make it accessible to most patients already exist. The limiting factor is often whether providers take a few minutes at the point of prescribing to connect patients with those tools. For help locating pharmacies with COVID-19 antivirals in stock for your patients, visit medfinder for providers — a service that calls pharmacies on your patients' behalf and texts them results.